tiprankstipranks
SciBase Holding AB (SE:SCIB)
:SCIB
Want to see SE:SCIB full AI Analyst Report?

SciBase Holding AB (SCIB) AI Stock Analysis

0 Followers

Top Page

SE:SCIB

SciBase Holding AB

(SCIB)

Select Model
Select Model
Select Model
Neutral 42 (OpenAI - Gpt-5.6Sol)
Rating:42Neutral
Price Target:
kr18.50
▲(5506.06% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily held down by weak financial fundamentals—very large losses and substantial ongoing cash burn—despite improving revenue growth and a healthy gross margin. Technicals also remain bearish with the price below major moving averages, while valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Improving revenue trajectory
The return to stronger growth indicates improving adoption of SciBase’s diagnostic platform. Sustained expansion can increase installed systems and test volumes, supporting operating leverage if the company controls its cost base.
Negative Factors
Deep and persistent losses
Losses remain far too large relative to revenue, showing that the operating cost base is well ahead of current scale. Without substantial margin expansion or expense discipline, growth may not translate into self-sustaining profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue trajectory
The return to stronger growth indicates improving adoption of SciBase’s diagnostic platform. Sustained expansion can increase installed systems and test volumes, supporting operating leverage if the company controls its cost base.
Read all positive factors

SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)

SciBase Holding AB Business Overview & Revenue Model

Company Description
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their k...
How the Company Makes Money
SciBase makes money primarily by selling and supporting its skin cancer detection solution (Nevisense) to healthcare providers and clinical customers. Revenue typically comes from (1) sales of capital equipment (the Nevisense device/system) placed...

SciBase Holding AB Financial Statement Overview

Summary
Revenue momentum improved (TTM revenue up ~14.2%) and gross margin is solid (~59%), but results are dominated by very large losses (TTM net margin around -208%) and heavy cash burn (TTM operating cash flow about -97.8M; free cash flow ~-98.4M), implying ongoing funding/dilution risk. Balance sheet leverage is currently moderate (debt-to-equity ~0.41) but has been volatile and could weaken again if losses persist.
Income Statement
22
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue52.40M40.46M29.70M23.25M17.89M11.73M
Gross Profit29.14M27.10M21.08M16.04M11.23M6.58M
EBITDA-80.74M-81.49M-57.59M-51.83M-39.33M-38.58M
Net Income-97.52M-87.06M-61.13M-55.59M-39.90M-41.69M
Balance Sheet
Total Assets72.98M52.17M61.73M64.33M49.85M85.46M
Cash, Cash Equivalents and Short-Term Investments37.15M22.60M11.24M34.12M18.83M65.61M
Total Debt23.21M23.03M4.18M6.80M8.12M2.86M
Total Liabilities42.76M45.51M25.08M21.28M24.62M14.66M
Stockholders Equity30.22M6.66M36.65M43.06M25.24M70.80M
Cash Flow
Free Cash Flow-98.42M-84.81M-57.81M-52.37M-44.85M-40.12M
Operating Cash Flow-97.78M-84.58M-57.38M-51.98M-44.47M-39.50M
Investing Cash Flow-733.00K-228.00K-428.00K-383.00K-381.00K-526.00K
Financing Cash Flow111.83M96.29M34.91M67.68M-2.48M64.22M

SciBase Holding AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.33
Price Trends
50DMA
29.59
Negative
100DMA
36.84
Negative
200DMA
31.95
Negative
Market Momentum
MACD
-3.30
Positive
RSI
15.24
Positive
STOCH
1.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 24.30, below the 50-day MA of 29.59, and below the 200-day MA of 31.95, indicating a bearish trend. The MACD of -3.30 indicates Positive momentum. The RSI at 15.24 is Positive, neither overbought nor oversold. The STOCH value of 1.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
kr57.60B100.0028.52%0.41%9.32%0.07%
60
Neutral
kr1.30B-251.15-1.22%34.05%-144.96%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
44
Neutral
kr558.90M-4.96-37.43%27.40%26.07%
43
Neutral
kr276.34M-6.93-100.09%65.82%41.28%
42
Neutral
kr198.37M-1.21-303.61%51.21%42.24%
41
Neutral
kr39.03M-0.20-57.15%16.02%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SCIB
SciBase Holding AB
19.20
-8.63
-31.02%
SE:PAX
Paxman AB
54.80
-22.40
-29.02%
SE:SEZI
Senzime AB
3.52
-2.63
-42.76%
SE:SPEC
SpectraCure AB
0.02
-0.11
-82.44%
SE:SECT.B
Sectra AB Class B
293.00
-29.71
-9.21%
SE:ACARIX
Acarix AB
0.24
-0.06
-19.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2026